Curation
PascalFrancis
Racine
Curation
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Rotigotine transdermal patch for the treatment of Parkinson's Disease

Identifieur interne : 001157 ( PascalFrancis/Curation ); précédent : 001156; suivant : 001158

Rotigotine transdermal patch for the treatment of Parkinson's Disease

Auteurs : Santiago Perez-Lloret [France, Argentine] ; Maria Veronica Rey [France] ; Pietro Lucca Ratti [France] ; Olivier Rascol [France]

Source :

RBID : Pascal:13-0074112

Descripteurs français

English descriptors

Abstract

Rotigotine, a non-ergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMEA marketing authorization for the treatment of adult patients with early or advanced Parkinson's disease (PD) or with moderate to severe restless legs syndrome (RLS). FDA originally granted a marketing authorization for early PD, which was later suspended, and is now studying the authorization for RLS. The aim of this review is to review the pharmacokinetics, pharmacodynamics as well as the clinical efficacy and tolerability of the rotigotine transdermal patch in PD. Source material was identified using a PubMed search for the term 'rotigotine' and PD. Articles published up to January 2011 or abstract submitted to most relevant international neurology congresses were reviewed. The rotigotine transdermal patch is efficacious for the treatment of PD. Tolerability profile appears to be well within the range of that observed with other non-ergot dopamine agonists in PD. Application-site reactions were the most frequent adverse event, and they were considered mild to moderate in the majority of cases. The rotigotine transdermal patch offers a safe and efficacious alternative for the treatment of PD. Further studies should focus on the possibility that continuous dopamine stimulation by means of the transdermal patch has any influence on levodopa-related motor complications.
pA  
A01 01  1    @0 0767-3981
A02 01      @0 FCPHEZ
A03   1    @0 Fundam. clin. pharmacol.
A05       @2 27
A06       @2 1
A08 01  1  ENG  @1 Rotigotine transdermal patch for the treatment of Parkinson's Disease
A11 01  1    @1 PEREZ-LLORET (Santiago)
A11 02  1    @1 VERONICA REY (Maria)
A11 03  1    @1 RATTI (Pietro Lucca)
A11 04  1    @1 RASCOL (Olivier)
A14 01      @1 Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse @2 Toulouse @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.
A14 02      @1 INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac @2 31059, TOULOUSE @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.
A14 03      @1 Clinical Pharmacology Center, Raul Carrea Institute for Neurological Research @2 Buenos Aires @3 ARG @Z 1 aut.
A20       @1 81-95
A21       @1 2013
A23 01      @0 ENG
A43 01      @1 INIST @2 14711 @5 354000506348730060
A44       @0 0000 @1 © 2013 INIST-CNRS. All rights reserved.
A45       @0 80 ref.
A47 01  1    @0 13-0074112
A60       @1 P
A61       @0 A
A64 01  1    @0 Fundamental & clinical pharmacology
A66 01      @0 GBR
C01 01    ENG  @0 Rotigotine, a non-ergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMEA marketing authorization for the treatment of adult patients with early or advanced Parkinson's disease (PD) or with moderate to severe restless legs syndrome (RLS). FDA originally granted a marketing authorization for early PD, which was later suspended, and is now studying the authorization for RLS. The aim of this review is to review the pharmacokinetics, pharmacodynamics as well as the clinical efficacy and tolerability of the rotigotine transdermal patch in PD. Source material was identified using a PubMed search for the term 'rotigotine' and PD. Articles published up to January 2011 or abstract submitted to most relevant international neurology congresses were reviewed. The rotigotine transdermal patch is efficacious for the treatment of PD. Tolerability profile appears to be well within the range of that observed with other non-ergot dopamine agonists in PD. Application-site reactions were the most frequent adverse event, and they were considered mild to moderate in the majority of cases. The rotigotine transdermal patch offers a safe and efficacious alternative for the treatment of PD. Further studies should focus on the possibility that continuous dopamine stimulation by means of the transdermal patch has any influence on levodopa-related motor complications.
C02 01  X    @0 002B02
C02 02  X    @0 002B17G
C02 03  X    @0 002B17A01
C03 01  X  FRE  @0 Rotigotine @2 NK @2 FR @5 01
C03 01  X  ENG  @0 Rotigotine @2 NK @2 FR @5 01
C03 01  X  SPA  @0 Rotigotina @2 NK @2 FR @5 01
C03 02  X  FRE  @0 Voie percutanée @5 02
C03 02  X  ENG  @0 Percutaneous route @5 02
C03 02  X  SPA  @0 Vía percutánea @5 02
C03 03  X  FRE  @0 Système transdermique @5 03
C03 03  X  ENG  @0 Transdermal system @5 03
C03 03  X  SPA  @0 Sistema transdérmico @5 03
C03 04  X  FRE  @0 Patch @5 04
C03 04  X  ENG  @0 Patch @5 04
C03 04  X  SPA  @0 Parche @5 04
C03 05  X  FRE  @0 Traitement @5 05
C03 05  X  ENG  @0 Treatment @5 05
C03 05  X  SPA  @0 Tratamiento @5 05
C03 06  X  FRE  @0 Maladie de Parkinson @2 NM @5 06
C03 06  X  ENG  @0 Parkinson disease @2 NM @5 06
C03 06  X  SPA  @0 Parkinson enfermedad @2 NM @5 06
C03 07  X  FRE  @0 Stimulant dopaminergique @5 07
C03 07  X  ENG  @0 Dopamine agonist @5 07
C03 07  X  SPA  @0 Estimulante dopaminérgico @5 07
C03 08  X  FRE  @0 Efficacité traitement @5 08
C03 08  X  ENG  @0 Treatment efficiency @5 08
C03 08  X  SPA  @0 Eficacia tratamiento @5 08
C03 09  X  FRE  @0 Syndrome des jambes sans repos @5 09
C03 09  X  ENG  @0 Restless legs syndrome @5 09
C03 09  X  SPA  @0 Acroparestesia nocturna @5 09
C03 10  X  FRE  @0 Toxicité @5 10
C03 10  X  ENG  @0 Toxicity @5 10
C03 10  X  SPA  @0 Toxicidad @5 10
C03 11  X  FRE  @0 Sécurité @5 11
C03 11  X  ENG  @0 Safety @5 11
C03 11  X  SPA  @0 Seguridad @5 11
C03 12  X  FRE  @0 Antiparkinsonien @5 23
C03 12  X  ENG  @0 Antiparkinson agent @5 23
C03 12  X  SPA  @0 Antiparkinsoniano @5 23
C07 01  X  FRE  @0 Agoniste @5 37
C07 01  X  ENG  @0 Agonist @5 37
C07 01  X  SPA  @0 Agonista @5 37
C07 02  X  FRE  @0 Récepteur dopaminergique @5 38
C07 02  X  ENG  @0 Dopamine receptor @5 38
C07 02  X  SPA  @0 Receptor dopaminérgico @5 38
C07 03  X  FRE  @0 Récepteur dopaminergique D1 @5 39
C07 03  X  ENG  @0 D1 Dopamine receptor @5 39
C07 03  X  SPA  @0 Receptor dopaminérgico D1 @5 39
C07 04  X  FRE  @0 Récepteur dopaminergique D2 @5 40
C07 04  X  ENG  @0 D2 Dopamine receptor @5 40
C07 04  X  SPA  @0 Receptor dopaminérgico D2 @5 40
C07 05  X  FRE  @0 Récepteur dopaminergique D3 @5 41
C07 05  X  ENG  @0 D3 Dopamine receptor @5 41
C07 05  X  SPA  @0 Receptor dopaminérgico D3 @5 41
C07 06  X  FRE  @0 Système administration @5 42
C07 06  X  ENG  @0 Delivery system @5 42
C07 06  X  SPA  @0 Sistema administración @5 42
C07 07  X  FRE  @0 Forme pharmaceutique @5 43
C07 07  X  ENG  @0 Dosage form @5 43
C07 07  X  SPA  @0 Forma farmacéutica @5 43
C07 08  X  FRE  @0 Maladie dégénérative @5 44
C07 08  X  ENG  @0 Degenerative disease @5 44
C07 08  X  SPA  @0 Enfermedad degenerativa @5 44
C07 09  X  FRE  @0 Pathologie du système nerveux @5 45
C07 09  X  ENG  @0 Nervous system diseases @5 45
C07 09  X  SPA  @0 Sistema nervioso patología @5 45
C07 10  X  FRE  @0 Pathologie de l'encéphale @5 46
C07 10  X  ENG  @0 Cerebral disorder @5 46
C07 10  X  SPA  @0 Encéfalo patología @5 46
C07 11  X  FRE  @0 Syndrome extrapyramidal @5 47
C07 11  X  ENG  @0 Extrapyramidal syndrome @5 47
C07 11  X  SPA  @0 Extrapiramidal síndrome @5 47
C07 12  X  FRE  @0 Pathologie du système nerveux central @5 48
C07 12  X  ENG  @0 Central nervous system disease @5 48
C07 12  X  SPA  @0 Sistema nervosio central patología @5 48
C07 13  X  FRE  @0 Trouble neurologique @5 49
C07 13  X  ENG  @0 Neurological disorder @5 49
C07 13  X  SPA  @0 Trastorno neurológico @5 49
C07 14  X  FRE  @0 Trouble de la sensibilité @5 50
C07 14  X  ENG  @0 Sensitivity disorder @5 50
C07 14  X  SPA  @0 Trastorno sensibilidad @5 50
N21       @1 042
N44 01      @1 OTO
N82       @1 OTO

Links toward previous steps (curation, corpus...)

Links to Exploration step

Pascal:13-0074112

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Rotigotine transdermal patch for the treatment of Parkinson's Disease</title>
<author>
<name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1>
<s2>31059, TOULOUSE</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Clinical Pharmacology Center, Raul Carrea Institute for Neurological Research</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Argentine</country>
</affiliation>
</author>
<author>
<name sortKey="Veronica Rey, Maria" sort="Veronica Rey, Maria" uniqKey="Veronica Rey M" first="Maria" last="Veronica Rey">Maria Veronica Rey</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1>
<s2>31059, TOULOUSE</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Ratti, Pietro Lucca" sort="Ratti, Pietro Lucca" uniqKey="Ratti P" first="Pietro Lucca" last="Ratti">Pietro Lucca Ratti</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1>
<s2>31059, TOULOUSE</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1>
<s2>31059, TOULOUSE</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">13-0074112</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0074112 INIST</idno>
<idno type="RBID">Pascal:13-0074112</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000133</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001157</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Rotigotine transdermal patch for the treatment of Parkinson's Disease</title>
<author>
<name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1>
<s2>31059, TOULOUSE</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Clinical Pharmacology Center, Raul Carrea Institute for Neurological Research</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Argentine</country>
</affiliation>
</author>
<author>
<name sortKey="Veronica Rey, Maria" sort="Veronica Rey, Maria" uniqKey="Veronica Rey M" first="Maria" last="Veronica Rey">Maria Veronica Rey</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1>
<s2>31059, TOULOUSE</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Ratti, Pietro Lucca" sort="Ratti, Pietro Lucca" uniqKey="Ratti P" first="Pietro Lucca" last="Ratti">Pietro Lucca Ratti</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1>
<s2>31059, TOULOUSE</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1>
<s2>31059, TOULOUSE</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Fundamental & clinical pharmacology</title>
<title level="j" type="abbreviated">Fundam. clin. pharmacol.</title>
<idno type="ISSN">0767-3981</idno>
<imprint>
<date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Fundamental & clinical pharmacology</title>
<title level="j" type="abbreviated">Fundam. clin. pharmacol.</title>
<idno type="ISSN">0767-3981</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antiparkinson agent</term>
<term>Dopamine agonist</term>
<term>Parkinson disease</term>
<term>Patch</term>
<term>Percutaneous route</term>
<term>Restless legs syndrome</term>
<term>Rotigotine</term>
<term>Safety</term>
<term>Toxicity</term>
<term>Transdermal system</term>
<term>Treatment</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Rotigotine</term>
<term>Voie percutanée</term>
<term>Système transdermique</term>
<term>Patch</term>
<term>Traitement</term>
<term>Maladie de Parkinson</term>
<term>Stimulant dopaminergique</term>
<term>Efficacité traitement</term>
<term>Syndrome des jambes sans repos</term>
<term>Toxicité</term>
<term>Sécurité</term>
<term>Antiparkinsonien</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Rotigotine, a non-ergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMEA marketing authorization for the treatment of adult patients with early or advanced Parkinson's disease (PD) or with moderate to severe restless legs syndrome (RLS). FDA originally granted a marketing authorization for early PD, which was later suspended, and is now studying the authorization for RLS. The aim of this review is to review the pharmacokinetics, pharmacodynamics as well as the clinical efficacy and tolerability of the rotigotine transdermal patch in PD. Source material was identified using a PubMed search for the term 'rotigotine' and PD. Articles published up to January 2011 or abstract submitted to most relevant international neurology congresses were reviewed. The rotigotine transdermal patch is efficacious for the treatment of PD. Tolerability profile appears to be well within the range of that observed with other non-ergot dopamine agonists in PD. Application-site reactions were the most frequent adverse event, and they were considered mild to moderate in the majority of cases. The rotigotine transdermal patch offers a safe and efficacious alternative for the treatment of PD. Further studies should focus on the possibility that continuous dopamine stimulation by means of the transdermal patch has any influence on levodopa-related motor complications.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0767-3981</s0>
</fA01>
<fA02 i1="01">
<s0>FCPHEZ</s0>
</fA02>
<fA03 i2="1">
<s0>Fundam. clin. pharmacol.</s0>
</fA03>
<fA05>
<s2>27</s2>
</fA05>
<fA06>
<s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Rotigotine transdermal patch for the treatment of Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>PEREZ-LLORET (Santiago)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>VERONICA REY (Maria)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>RATTI (Pietro Lucca)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>RASCOL (Olivier)</s1>
</fA11>
<fA14 i1="01">
<s1>Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>INSERM CIC-9023 and UMR-825), Pavillon Riser, Hôpital Purpan, Place du Docteur Baylac</s1>
<s2>31059, TOULOUSE</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Clinical Pharmacology Center, Raul Carrea Institute for Neurological Research</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA20>
<s1>81-95</s1>
</fA20>
<fA21>
<s1>2013</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>14711</s2>
<s5>354000506348730060</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>80 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>13-0074112</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Fundamental & clinical pharmacology</s0>
</fA64>
<fA66 i1="01">
<s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Rotigotine, a non-ergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMEA marketing authorization for the treatment of adult patients with early or advanced Parkinson's disease (PD) or with moderate to severe restless legs syndrome (RLS). FDA originally granted a marketing authorization for early PD, which was later suspended, and is now studying the authorization for RLS. The aim of this review is to review the pharmacokinetics, pharmacodynamics as well as the clinical efficacy and tolerability of the rotigotine transdermal patch in PD. Source material was identified using a PubMed search for the term 'rotigotine' and PD. Articles published up to January 2011 or abstract submitted to most relevant international neurology congresses were reviewed. The rotigotine transdermal patch is efficacious for the treatment of PD. Tolerability profile appears to be well within the range of that observed with other non-ergot dopamine agonists in PD. Application-site reactions were the most frequent adverse event, and they were considered mild to moderate in the majority of cases. The rotigotine transdermal patch offers a safe and efficacious alternative for the treatment of PD. Further studies should focus on the possibility that continuous dopamine stimulation by means of the transdermal patch has any influence on levodopa-related motor complications.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B02</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X">
<s0>002B17A01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Rotigotine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Rotigotine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Rotigotina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Voie percutanée</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Percutaneous route</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Vía percutánea</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Système transdermique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Transdermal system</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Sistema transdérmico</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Patch</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Patch</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Parche</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Traitement</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Treatment</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Tratamiento</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Stimulant dopaminergique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Dopamine agonist</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Estimulante dopaminérgico</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Efficacité traitement</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Treatment efficiency</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Eficacia tratamiento</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Syndrome des jambes sans repos</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Restless legs syndrome</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Acroparestesia nocturna</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Toxicité</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Toxicity</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Toxicidad</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Sécurité</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Safety</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Seguridad</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Antiparkinsonien</s0>
<s5>23</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Antiparkinson agent</s0>
<s5>23</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Antiparkinsoniano</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Agoniste</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Agonist</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Agonista</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Récepteur dopaminergique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Dopamine receptor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Receptor dopaminérgico</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Récepteur dopaminergique D1</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>D1 Dopamine receptor</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Receptor dopaminérgico D1</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Récepteur dopaminergique D2</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>D2 Dopamine receptor</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Receptor dopaminérgico D2</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Récepteur dopaminergique D3</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>D3 Dopamine receptor</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Receptor dopaminérgico D3</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Système administration</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Delivery system</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Sistema administración</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Forme pharmaceutique</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Dosage form</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Forma farmacéutica</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>44</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE">
<s0>Pathologie du système nerveux</s0>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>45</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE">
<s0>Pathologie de l'encéphale</s0>
<s5>46</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>46</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>46</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE">
<s0>Syndrome extrapyramidal</s0>
<s5>47</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>47</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>47</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE">
<s0>Pathologie du système nerveux central</s0>
<s5>48</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>48</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>48</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE">
<s0>Trouble neurologique</s0>
<s5>49</s5>
</fC07>
<fC07 i1="13" i2="X" l="ENG">
<s0>Neurological disorder</s0>
<s5>49</s5>
</fC07>
<fC07 i1="13" i2="X" l="SPA">
<s0>Trastorno neurológico</s0>
<s5>49</s5>
</fC07>
<fC07 i1="14" i2="X" l="FRE">
<s0>Trouble de la sensibilité</s0>
<s5>50</s5>
</fC07>
<fC07 i1="14" i2="X" l="ENG">
<s0>Sensitivity disorder</s0>
<s5>50</s5>
</fC07>
<fC07 i1="14" i2="X" l="SPA">
<s0>Trastorno sensibilidad</s0>
<s5>50</s5>
</fC07>
<fN21>
<s1>042</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001157 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001157 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:13-0074112
   |texte=   Rotigotine transdermal patch for the treatment of Parkinson's Disease
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024